NASDAQ:CNCE

Concert Pharmaceuticals to Present at H.C. Wainwright Global Investment Conference

Retrieved on: 
Tuesday, September 6, 2022
Health, General Health, Clinical Trials, Research, Science, Pharmaceutical, Biotechnology, Twitter, CNCE, Medication, Investor, Webcast, Conference, Alopecia areata, LinkedIn, Company, NASDAQ, Pharmaceutical industry

Concert Pharmaceuticals, Inc. (NASDAQ: CNCE) today announced that it will participate virtually at the H.C. Wainwright 24th Annual Global Investment Conference, and its presentation will be available beginning at 7:00 a.m.

Key Points: 
  • Concert Pharmaceuticals, Inc. (NASDAQ: CNCE) today announced that it will participate virtually at the H.C. Wainwright 24th Annual Global Investment Conference, and its presentation will be available beginning at 7:00 a.m.
  • The on-demand webcast of the presentation may be accessed in the Investors section of the Companys website at www.concertpharma.com .
  • Concert Pharmaceuticals is a late-stage clinical biopharmaceutical company that is developing CTP-543 , a novel oral JAK1/2 inhibitor.
  • Concert has successfully completed two Phase 3 trials with CTP-543 in adults with alopecia areata, a serious autoimmune dermatological condition.

Bridges and Landmarks Across the USA Will Illuminate Blue Throughout the Month of September for Alopecia Areata

Retrieved on: 
Thursday, September 1, 2022
Social Media, Pharmaceutical, Health, Communications, Social Activism, Philanthropy, Foundation, Other Health

In recognition of Alopecia Areata Awareness Month, bridges, buildings and other landmarks across the United States will be illuminated blue to raise awareness for this serious autoimmune disease.

Key Points: 
  • In recognition of Alopecia Areata Awareness Month, bridges, buildings and other landmarks across the United States will be illuminated blue to raise awareness for this serious autoimmune disease.
  • The effort will unite U.S. cities in observance of Alopecia Areata Awareness Month, which is recognized annually during September.
  • Help us light up the night sky by reaching out to local landmarks to request a blue illumination for Alopecia Areata Awareness Month, then post a photo with #LightItUpBlue4AlopeciaAreata.
  • The Light It Up Blue 4 Alopecia Areata campaign is made possible by Concert Pharmaceuticals, Inc.
    View source version on businesswire.com: https://www.businesswire.com/news/home/20220901005178/en/

Concert Pharmaceuticals Announces That Results From CTP-543 THRIVE‑AA1 Phase 3 Trial in Patients With Alopecia Areata Selected for Late Breaking Presentation at EADV Congress

Retrieved on: 
Monday, August 22, 2022
Biotechnology, Health, Science, Pharmaceutical, Research, Janus, Severity, Yale School of Medicine, Security (finance), Safety, DCE, Autoimmune disease, Alopecia areata, Hair, NASDAQ, JAK2, Disease, Man, Medication, Deuterium, Journal of the European Academy of Dermatology and Venereology, SALT, Private Securities Litigation Reform Act, Anxiety, LinkedIn, Janus kinase, U.S. Securities and Exchange Commission, Depression, Patient, Breakthrough therapy, FDA, Immune system, Twitter, Adult, CNCE, JAK1, Congress, Scalp, Woman, Clinical trial, Life, Moderate, Pharmaceutical industry, Venereology, Dermatology

Concert Pharmaceuticals, Inc. (NASDAQ: CNCE) today announced that results from the first Phase 3 clinical trial of CTP-543 (THRIVE-AA1) in adult patients with moderate to severe alopecia areata will be presented as a late breaking oral presentation at the 31st European Academy of Dermatology and Venereology (EADV) Congress.

Key Points: 
  • Concert Pharmaceuticals, Inc. (NASDAQ: CNCE) today announced that results from the first Phase 3 clinical trial of CTP-543 (THRIVE-AA1) in adult patients with moderate to severe alopecia areata will be presented as a late breaking oral presentation at the 31st European Academy of Dermatology and Venereology (EADV) Congress.
  • The FDA has granted CTP-543 Breakthrough Therapy designation for the treatment of adult patients with moderate to severe alopecia areata and Fast Track designation for the treatment of alopecia areata.
  • Alopecia areata is an autoimmune disease in which the immune system attacks hair follicles, resulting in partial or complete loss of hair on the scalp and body.
  • Concerts lead product candidate CTP-543 is being developed for the treatment of alopecia areata, a serious autoimmune dermatological condition.

Concert Pharmaceuticals Announces Exercise of Warrants Under Existing Financing Arrangement

Retrieved on: 
Monday, August 22, 2022
Health, Health Technology, Other Science, Clinical Trials, Science, Pharmaceutical, Biotechnology, Security (finance), NDA, DCE, RA, Alopecia areata, NASDAQ, Exercise, Medication, Deuterium, New Drug Application, Private Securities Litigation Reform Act, LinkedIn, Investment, U.S. Securities and Exchange Commission, Company, Twitter, CNCE, Clinical trial, BVF, Pharmaceutical industry

The exercise period of the tranche 1 and tranche 2 warrants was tied to the clinical success of the Companys CTP-543 THRIVE-AA1 and THRIVE-AA2 Phase 3 trials for alopecia areata.

Key Points: 
  • The exercise period of the tranche 1 and tranche 2 warrants was tied to the clinical success of the Companys CTP-543 THRIVE-AA1 and THRIVE-AA2 Phase 3 trials for alopecia areata.
  • Concert reported positive topline results from the THRIVE-AA1 and THRIVE-AA2 trials in May 2022 and August 2022, respectively.
  • In June 2022, Concert received $18.9 million from the partial exercise of the tranche 1 warrants issued to BVF and RA Capital.
  • Concert Pharmaceuticals is a late-stage clinical biopharmaceutical company that is developing small molecule drugs that it discovered through the application of its DCE Platform (deuterated chemical entity platform).

Concert Pharmaceuticals Reports Second Quarter 2022 Financial Results

Retrieved on: 
Thursday, August 4, 2022
Health, Other Health, General Health, Clinical Trials, Research, Science, Pharmaceutical, Medication, Patient, Company, Alopecia areata, SALT, Hair, Safety, NASDAQ, FDA, CNCE, Pharmaceutical industry, New Drug Application

Concert Pharmaceuticals, Inc. (NASDAQ: CNCE) today reported financial results for the second quarter of 2022.

Key Points: 
  • Concert Pharmaceuticals, Inc. (NASDAQ: CNCE) today reported financial results for the second quarter of 2022.
  • In May 2022, the Company reported positive topline results for its first CTP-543 Phase 3 clinical trial.
  • In August 2022, the Company reported positive topline results for its second CTP-543 Phase 3 clinical trial.
  • ET to provide an update on the Company and discuss second quarter financial results.

Concert Pharmaceuticals Reports Positive Topline Results for Second CTP‑543 Phase 3 Clinical Trial in Alopecia Areata

Retrieved on: 
Monday, August 1, 2022
Biotechnology, Other Health, Health, Pharmaceutical, Clinical Trials, Patient, Medication, Degenerative disease, SALT, CNCE, NDA, Adult, Alopecia areata, Patient satisfaction, NASDAQ, MD, Week, Â, Hair, Autoimmune disease, Population, Pharmaceutical industry

Concert Pharmaceuticals, Inc. (NASDAQ: CNCE) today announced positive topline results from its second Phase 3 clinical trial, THRIVE-AA2, evaluating its oral investigational medicine CTP-543 in adult patients with moderate to severe alopecia areata, an autoimmune disorder that results in patchy or complete scalp hair loss.

Key Points: 
  • Concert Pharmaceuticals, Inc. (NASDAQ: CNCE) today announced positive topline results from its second Phase 3 clinical trial, THRIVE-AA2, evaluating its oral investigational medicine CTP-543 in adult patients with moderate to severe alopecia areata, an autoimmune disorder that results in patchy or complete scalp hair loss.
  • These results are very promising and suggest that CTP-543 has the potential to address important needs for people living with alopecia areata.
  • Patients enrolled in THRIVE-AA2 were required to have at least 50 percent scalp hair loss due to alopecia areata, as measured by SALT.
  • The FDA has granted CTP-543 Breakthrough Therapy designation for the treatment of adult patients with moderate to severe alopecia areata and Fast Track designation for the treatment of alopecia areata.

Concert Pharmaceuticals to Report Second Quarter 2022 Results on August 4, 2022

Retrieved on: 
Friday, July 29, 2022
Biotechnology, Pharmaceutical, Health, NASDAQ, PIN, Webcast, DCE, Deuterium, Medication, Alopecia areata, Investor, Company, CNCE, Twitter, LinkedIn, Pharmaceutical industry

Concert Pharmaceuticals, Inc. (NASDAQ: CNCE) today announced that it will report its financial results for the second quarter of 2022, on Thursday, August 4, 2022, before the U.S. financial markets open.

Key Points: 
  • Concert Pharmaceuticals, Inc. (NASDAQ: CNCE) today announced that it will report its financial results for the second quarter of 2022, on Thursday, August 4, 2022, before the U.S. financial markets open.
  • ET to discuss its second quarter 2022 financial results and provide a business update.
  • Please note that there is a new system to access the live call in order to ask questions.
  • Concert Pharmaceuticals is a clinical stage biopharmaceutical company that is developing small molecule drugs that it discovered through the application of its DCE Platform (deuterated chemical entity platform).

Concert Pharmaceuticals to Participate in Fireside Chat at The JMP Securities Life Sciences Conference

Retrieved on: 
Thursday, June 9, 2022
Biotechnology, Pharmaceutical, Health, Clinical Trials, DCE, Conference, JMP, LinkedIn, Webcast, Investor, Medication, Alopecia areata, NASDAQ, Twitter, CNCE, Deuterium, The, Pharmaceutical industry

Concert Pharmaceuticals, Inc. (NASDAQ: CNCE) today announced that it will participate in a fireside chat at The JMP Securities Life Sciences Conference on June 16, 2022 at 1:00 p.m.

Key Points: 
  • Concert Pharmaceuticals, Inc. (NASDAQ: CNCE) today announced that it will participate in a fireside chat at The JMP Securities Life Sciences Conference on June 16, 2022 at 1:00 p.m.
  • A webcast of the JMP fireside chat may be accessed in the Investors section of the Companys website at www.concertpharma.com .
  • A replay of the webcast will be available on Concerts website for two weeks following the presentation.
  • Concert Pharmaceuticals is a clinical stage biopharmaceutical company that is developing small molecule drugs that it discovered through the application of its DCE Platform (deuterated chemical entity platform).

Phase 2 Dose‑Ranging Clinical Trial Results of CTP‑543 in Patients with Alopecia Areata published in the Journal of the American Academy of Dermatology

Retrieved on: 
Tuesday, June 7, 2022
Biotechnology, Pharmaceutical, Health, Clinical Trials, Janus, Breakthrough therapy, Adult, Company, Journal, Hair, Dermatology, Food, American Academy, Hair loss, Medication, Breakthrough, Autoimmunity, Alopecia areata, FDA, JAK, Patient, JAAD, Immune system, Autoimmune disease, NASDAQ, Department, Severity, CNCE, Literature, Regulation of tobacco by the U.S. Food and Drug Administration, SALT, Yale School of Medicine, Safety, Pharmaceutical industry

The publication highlights the establishment of two doses of CTP-543 with statistically significant hair regrowth and a generally well tolerated safety profile in patients with moderate to severe alopecia areata.

Key Points: 
  • The publication highlights the establishment of two doses of CTP-543 with statistically significant hair regrowth and a generally well tolerated safety profile in patients with moderate to severe alopecia areata.
  • The robust clinical results observed in the trial supported the Breakthrough Therapy designation from the U.S. Food and Drug Administration (FDA) and the progression of CTP-543 into the THRIVE-AA pivotal Phase 3 clinical program.
  • The Company recently reported positive topline data from the THRIVE-AA1 trial, and topline data from the THRIVE-AA2 trial is expected in the third quarter of 2022.
  • The Phase 2 trial was a randomized, double-blind, placebo-controlled, sequential dose trial to evaluate the safety and efficacy of CTP-543 in adult patients with moderate to severe alopecia areata.

Concert Pharmaceuticals Raises Gross Proceeds of $66.4 Million Through Public Offering and Exercise of Warrants

Retrieved on: 
Monday, June 6, 2022
Biotechnology, Pharmaceutical, Health, Clinical Trials, Exercise, Madison Avenue, DCE, RA, Jefferies, Mizuho Securities, Telephone, Security (finance), U.S. Securities and Exchange Commission, Medication, Alopecia areata, Sale, Prospectus, NASDAQ, SEC, Jefferies Group, Attention, CNCE, Deuterium

Concert Pharmaceuticals, Inc. (NASDAQ: CNCE) today announced the closing of its previously announced underwritten public offering of 10,000,000 shares of its common stock to the public at $4.75 per share.

Key Points: 
  • Concert Pharmaceuticals, Inc. (NASDAQ: CNCE) today announced the closing of its previously announced underwritten public offering of 10,000,000 shares of its common stock to the public at $4.75 per share.
  • The aggregate gross proceeds to Concert from this offering were $47.5 million, before deducting underwriting discounts and commissions and other offering expenses payable by Concert.
  • Concert also announced the receipt of $18.9 million upon the exercise of tranche 1 warrants to purchase 3,981 shares of Series X1 Preferred Stock issued to BVF Partners L.P. and RA Capital Management in November 2021.
  • Through the public offering and warrant exercise, Concert raised aggregate gross proceeds of $66.4 million.